The U.S. Food and Drug Administration has approved Restylane Contour for correction of temple hollowing. The brief announcement names the regulatory action and the new indication; it names nothing else.

Temple hollowing describes the concave depression at the lateral forehead, between the orbital rim and the temporal hairline, that arises from age-related soft-tissue and bony volume loss. Clinicians have long addressed it with off-label hyaluronic acid injection, autologous fat transfer, and biostimulatory fillers (injectables that prompt collagen production rather than add direct volume), even though the FDA-labeled options for that specific anatomy remain narrow.

What does the source actually disclose?

The disclosure names two facts. The FDA approved the device, and the new indication is temple hollowing. The notice does not name the manufacturer, the approval date, the device's formulation, or the cohort enrolled in the supporting trial. It cites no primary endpoint, no effect size, and no peer-reviewed publication. No agency or manufacturer spokesperson appears in the text. No clinician can extract those details from the headline alone.

Why does the silence matter?

A supplemental indication for a previously approved soft-tissue filler normally arrives with a clinical study report detailing patient count, validated volume or severity scales, and durability of effect at six to twelve months. Without those figures, no practicing dermatologist can benchmark the new temple indication against existing off-label practice or against competitor fillers already in market. The skeptic's question — what is not said — applies with unusual force.

What is the regulatory pathway for a new anatomic indication?

A hyaluronic acid filler that has already received Premarket Approval (PMA) for one facial area can extend its label through a supplemental PMA (sPMA). The supplemental filing reuses the original safety dossier and adds targeted efficacy evidence in the new anatomy. Whether the Restylane Contour temple approval moved through that pathway, or through a different mechanism, the source does not state. The PMA supplement number — a routine identifier in any FDA approval announcement — does not appear in the notice.

What about cost and access?

Medicare and commercial insurance do not reimburse aesthetic indications, and any new label travels with a manufacturer-set wholesale acquisition cost (WAC). The source provides no pricing figure, no syringe volume, and no estimate of correction duration per treatment. A practice weighing inventory must wait for distributor notices, which typically follow the manufacturer's investor communication by several days.

How should the practicing dermatologist read this?

The news is real and material: a new on-label option for temple volume loss now exists. The supporting evidence base, however, remains unverified by the source. A practice weighing inventory and training should wait for the manufacturer's release and the FDA approval letter. Those documents will disclose the labeled syringe volume, the recommended injection depth and device (needle versus cannula), the postmarket follow-up commitment, and the decision date. Until then, the cautious position is to log the regulatory event without yet changing the practice pattern.

The next concrete signal to watch is the manufacturer's investor disclosure and the FDA's device classification database, where the PMA supplement number, the decision date, and the labeled indications will appear in standard form. Dermatologists who treat temple volume loss will then have, alongside the off-label hyaluronic acid and biostimulator options they already use, an explicitly FDA-labeled alternative — with the supporting data ready to examine.